A systematic review and meta-analysis of studies assessing pregnancy and neonatal outcomes of women with immune-mediated inflammatory diseases (including IBD, rheumatoid arthritis, and psoriasis) exposed to anti-TNF agents during pregnancy demonstrated an adequate immune response to tetanus, Streptococcus pneumoniae, diphtheria, and hepatitis B virus [313]. The gene discussed is TNF; the disease is inflammatory bowel disease.